Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Rhea-AI Summary
Phio Pharmaceuticals (NASDAQ: PHIO) will present in a live Virtual Non-Deal Roadshow on April 29, 2026 at 12 PM EDT. CEO Robert Bitterman will overview the INTASYL siRNA platform, discuss PH-762 clinical progress, and host a live Q&A.
Phio reported 22 patients completed Phase 1b across five dose cohorts with no dose-limiting toxicities or serious adverse events; pathological response in cSCC was ~65% overall and 85% (6 of 7) in the highest-dose cohort.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – PHIO
On the day this news was published, PHIO declined 1.60%, reflecting a mild negative market reaction. This price movement removed approximately $236K from the company's valuation, bringing the market cap to $14.52M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PHIO was flat while peers showed mixed moves: gains in APLM (+2.35%) contrasted with declines in ADAP (-17.57%) and others, pointing to stock-specific drivers rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 13 | Investor fireside chat | Positive | +2.5% | Virtual fireside chat highlighting INTASYL platform and PH-762 Phase 1b data. |
| Apr 09 | Conference presentation | Neutral | -3.9% | Centri Capital Conference presentation on clinical progress and PH-762 program. |
| Mar 30 | Manufacturing agreement | Positive | -4.8% | U.S. cGMP drug product manufacturing deal to supply PH-762 for trials and potential launch. |
| Mar 23 | Clinical data presentation | Positive | +2.5% | AAD 2026 presentation of Phase 1b PH-762 results in cutaneous carcinomas. |
| Mar 16 | Investor fireside chat | Positive | +7.3% | Virtual chat on INTASYL immuno-oncology approach and PH‑762 Phase 1b data. |
Recent news has focused on PH-762 clinical data and investor outreach, with mostly positive reactions to clinically oriented updates and mixed responses to event-focused communications.
Over the past months, Phio has repeatedly highlighted Phase 1b data for PH-762, with 22 patients treated, no dose-limiting toxicities and ~65% pathological response in cSCC, including 85% at the highest dose. Announcements on fireside chats, conference presentations, and a cGMP manufacturing agreement framed PH-762 as the core value driver. Price reactions have varied, with some clinical and investor-relations events (e.g., Mar 16, Mar 23, Apr 13) drawing positive moves, while other updates saw modest pullbacks.
Regulatory & Risk Context
An effective S-3 shelf filed on Nov 20, 2025 covers resale of up to 11,763,800 warrant shares by existing holders. Phio would receive up to $24.5 million only if these warrants are exercised for cash, while recent ATM arrangements for up to $6,360,000 of common stock provide an additional, separate source of potential equity issuance.
Market Pulse Summary
This announcement continues Phio’s investor-outreach campaign, featuring a virtual non-deal roadshow to review its INTASYL siRNA platform and PH-762 data. Phase 1b results have shown 22 patients treated with no dose-limiting toxicities and ~65% pathological response in cSCC, including 85% at the highest dose. Recent filings highlight both clinical progress and active capital-raising tools, so monitoring future trial design updates, use of the $6.36M ATM, and warrant exercises remains important.
Key Terms
sirna medical
intratumoral medical
cutaneous squamous cell carcinoma medical
cSCC medical
merkel cell carcinoma medical
pathological response medical
immuno-oncology medical
AI-generated analysis. Not financial advice.
Live Presentation and Q&A: Wednesday, April 29, 2026 12 PM EDT
King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will provide an overview of the Company's INTASYL siRNA platform and discuss recent clinical progress and priorities, followed by a live Q&A.
Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately
"We look forward to sharing why we believe INTASYL represents a differentiated approach to immuno-oncology and our strategy for PH-762 as we plan for the next stage of development," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.
Phio's presentation and live Q&A will take place on Wednesday April 29, 2026, at 12 PM EDT in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.
REGISTER HERE: Renmark Virtual Non-Deal Roadshow NASDAQ - PHIO | Event Registration | Renmark Financial Communications
Please Note: If the link does not work, please copy and paste into your browser. To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.
A replay of the event may be accessed on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements regarding the anticipated benefits of our INTASYL™ RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel: (416)-644-2020 or (212)-812-7680
www.renmarkfinancial.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293854